Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematological and non-haematological malignancies. CAR-T-cell therapy can induce rapid and durable clinical responses, but is associated with unique a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Nat Rev Clin Oncol
Main Authors: Neelapu, Sattva S., Tummala, Sudhakar, Kebriaei, Partow, Wierda, William, Gutierrez, Cristina, Locke, Frederick L., Komanduri, Krishna V., Lin, Yi, Jain, Nitin, Daver, Naval, Westin, Jason, Gulbis, Alison M., Loghin, Monica E., de Groot, John F., Adkins, Sherry, Davis, Suzanne E., Rezvani, Katayoun, Hwu, Patrick, Shpall, Elizabeth J.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6733403/
https://ncbi.nlm.nih.gov/pubmed/28925994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2017.148
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares